Amelogenin is a negative regulator of osteoclastogenesis via downregulation of RANKL, M-CSF and fibronectin expression in osteoblasts

Miyuki Nishiguchi, Kenji Yuasa, Kan Saito, Emiko Fukumoto, Aya Yamada, Tomokazu Hasegawa, Keigo Yoshizaki, Yoko Kamasaki, Kazuaki Nonaka, Taku Fujiwara, Satoshi Fukumoto

研究成果: Contribution to journalArticle査読

27 被引用数 (Scopus)

抄録

Amelogenin is a novel enamel matrix protein. Knockout mice showed enhanced osteoclast formation and resorption of tooth cementum. This study investigated the effects of amelogenin on osteoclastogenesis. In co-cultures with calvaria osteoblasts and purified bone marrow cells, amelogenin inhibited osteoclastogenesis dramatically. Furthermore, amelogenin inhibited the expression of receptor activator of nuclear factor κB ligand (RANKL), macrophage-colony stimulating factor (M-CSF) and fibronectin in osteoblasts, while RANKL expression was induced by fibronectin and inhibited by treatment with fibronectin small interfering RNA. These results suggest that the inhibitory effects of amelogenin on osteoclastogenesis lead to downregulation of RANKL, M-CSF and fibronectin production in osteoblasts.

本文言語英語
ページ(範囲)237-243
ページ数7
ジャーナルArchives of Oral Biology
52
3
DOI
出版ステータス出版済み - 3 2007

All Science Journal Classification (ASJC) codes

  • 耳鼻咽喉科学
  • 歯科学(全般)
  • 細胞生物学

フィンガープリント

「Amelogenin is a negative regulator of osteoclastogenesis via downregulation of RANKL, M-CSF and fibronectin expression in osteoblasts」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル